openPR Logo
Press release

Retinitis Pigmentosa Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies

04-12-2023 05:32 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Retinitis Pigmentosa Pipeline Assessment (2023 Updates) |

As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Retinitis Pigmentosa Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Retinitis Pigmentosa Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Retinitis Pigmentosa Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Retinitis Pigmentosa Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinitis Pigmentosa treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Retinitis Pigmentosa market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Retinitis Pigmentosa Therapeutics Domain:
https://www.delveinsight.com/report-store/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Retinitis pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Retinitis Pigmentosa Therapeutics Analysis
There are approx. 25+ key companies which are developing the therapies for Retinitis pigmentosa. Currently, Nightstar Therapeutics/Biogen are leading the therapeutics market with their Retinitis pigmentosa drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Retinitis Pigmentosa Therapeutics Market Include:
• Acucela Inc
• Allegro Ophthalmics
• Allergan Plc
• Amarantus Bioscience Holdings Inc
• Amgen Inc
• Anabasis Pharma
• Applied Genetic Technologies Corp
• Asklepios BioPharmaceutical Inc
• Astellas Pharma Inc
• Caladrius Biosciences Inc
• Dompe Farmaceutici SpA
• Editas Medicine
• GenSight Biologics SA
• Grupo Ferrer Internacional SA
• ID Pharma Co Ltd
• Janssen Pharmaceutical
• jCyte
• MeiraGTx
• Nacuity Pharmaceuticals
• Nightstar Therapeutics/Biogen
• OiDE OptoEye
• ReNeuron
• SanBio
And Many Others

Retinitis pigmentosa Emerging and Marketed Drugs Covered in the Report Include:
• AAV8-RPGR: Nightstar Therapeutics/Biogen
• Risuteganib: Allegro Ophthalmics
• NPI 001: Nacuity Pharmaceuticals
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Retinitis Pigmentosa Current Treatment Patterns
4. Retinitis Pigmentosa - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Retinitis Pigmentosa Late-Stage Products (Phase-III)
7. Retinitis Pigmentosa Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Retinitis Pigmentosa Discontinued Products
13. Retinitis Pigmentosa Product Profiles
14. Retinitis Pigmentosa Key Companies
15. Retinitis Pigmentosa Key Products
16. Dormant and Discontinued Products
17. Retinitis Pigmentosa Unmet Needs
18. Retinitis Pigmentosa Future Perspectives
19. Retinitis Pigmentosa Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Retinitis Pigmentosa Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies here

News-ID: 3010625 • Views:

More Releases from DelveInsight Business Research LLP

Idiopathic Membranous Nephropathy Treatment Market Size Expected to Grow Major Growth by 2034, estimates DelveInsight
Idiopathic Membranous Nephropathy Treatment Market Size Expected to Grow Major G …
DelveInsight's "Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Complicated Urinary Tract Infection (cUTI), historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection (cUTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Explore Idiopathic Membranous Nephropathy Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Age-related Vision Dysfunction Treatment Market Size Expected to Grow Major Growth by 2034, estimates DelveInsight
Age-related Vision Dysfunction Treatment Market Size Expected to Grow Major Grow …
DelveInsight's "Age-related Vision Dysfunction Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Unlock key insights into the Age-related Vision Dysfunction Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and
Warm Autoimmune Hemolytic Anemia Market Size Expected to Grow Major Growth by 2034, According to DelveInsight | Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation, Annexon
Warm Autoimmune Hemolytic Anemia Market Size Expected to Grow Major Growth by 20 …
DelveInsight has released a new report, "Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast-2034", providing comprehensive insights into the disease, historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Explore epidemiology trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Warm Autoimmune Hemolytic Anemia Market Report • On 24
Biliary Tract Cancer Market Size Expected to Grow Major Growth by 2034, estimates DelveInsight
Biliary Tract Cancer Market Size Expected to Grow Major Growth by 2034, estimate …
DelveInsight's report, "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034", provides a comprehensive analysis of biliary tract cancer, including historical trends, epidemiological projections, and market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report evaluates current treatment practices, pipeline therapies, and the market share of existing and emerging interventions. It presents the current and forecasted market size for biliary tract

All 5 Releases


More Releases for Retinitis

Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be? In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic
Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be? In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic
Retinitis Pigmentosa Market Growth and Treatment Advancements
The retinitis pigmentosa (RP) market has garnered considerable attention in recent years due to its profound impact on individuals' lives. As one of the leading causes of hereditary blindness, RP is a genetic eye disorder that progressively leads to vision loss. The market for retinitis pigmentosa treatments was valued at USD 14.02 billion in 2023, and with significant advancements on the horizon, it is expected to reach USD 21.40 billion
Retinitis Pigmentosa Market Research and Market Share Insights
The Business Research Company recently released a comprehensive report on the Global Retinitis Pigmentosa Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside
Retinitis Pigmentosa (Retinitis) Market Analysis and Future Prospects for 2030
The world of the retinitis pigmentosa (retinitis) market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing